top of page
Search

Rapid Review: Chromosomal Translocations for MRCP Part 1

TL;DR

Rapid Review: Chromosomal Translocations is a high-yield MRCP Part 1 topic centred on recognising classic gene rearrangements and their associated malignancies. Most questions test pattern recognition—linking a specific translocation to a disease, prognosis, or treatment. Focus on the core list (e.g., t(9;22), t(15;17), t(8;14)) and avoid common mix-ups. Mastering this topic offers quick, reliable marks in the exam.


Why this matters

Chromosomal translocations are among the most frequently tested genetics concepts in MRCP Part 1, particularly within haematology. These structural rearrangements result in oncogenic fusion proteins or dysregulated gene expression, driving malignancy.

From an exam standpoint, the emphasis is not on molecular complexity but on clinical associations and recall under pressure. Candidates who can quickly match a translocation to its disease—and occasionally its treatment—gain a significant advantage.

For broader preparation, review the MRCP Part 1 overview and practise actively using Free MRCP MCQs.


Core high-yield translocations

The following table summarises the most frequently tested chromosomal translocations:

Translocation

Disease Association

Key Feature

t(9;22)

Chronic myeloid leukaemia (CML)

BCR-ABL tyrosine kinase

t(15;17)

Acute promyelocytic leukaemia (APL)

PML-RARA fusion

t(8;14)

Burkitt lymphoma

MYC activation

t(14;18)

Follicular lymphoma

BCL-2 overexpression

t(11;14)

Mantle cell lymphoma

Cyclin D1 activation

t(12;21)

Acute lymphoblastic leukaemia (ALL)

Good prognosis (paediatric)

t(1;19)

Pre-B ALL

Intermediate prognosis

t(8;21)

AML (favourable)

RUNX1 mutation

inv(16)

AML (M4 subtype)

Good prognosis

The 5 most tested subtopics

1. Chronic myeloid leukaemia (CML) – t(9;22)

  • Known as the Philadelphia chromosome

  • Produces BCR-ABL fusion protein

  • Treated with tyrosine kinase inhibitors (e.g., imatinib)

2. Acute promyelocytic leukaemia (APL) – t(15;17)

  • Medical emergency due to risk of disseminated intravascular coagulation (DIC)

  • Treated with all-trans retinoic acid (ATRA)

3. Burkitt lymphoma – t(8;14)

  • Involves MYC oncogene activation

  • Highly aggressive but chemotherapy-sensitive

  • Often associated with Epstein–Barr virus

4. Follicular lymphoma – t(14;18)

  • BCL-2 overexpression → reduced apoptosis

  • Typically indolent course

5. Mantle cell lymphoma – t(11;14)

  • Cyclin D1 overexpression → increased cell proliferation

  • More aggressive than follicular lymphoma

High-yield pattern recognition shortcuts

Use these quick associations in the exam:

  1. Chromosome 14 involvement → Immunoglobulin heavy chain → Lymphoma

  2. MYC → Rapid proliferation → Aggressive tumour

  3. BCL-2 → Anti-apoptosis → Indolent disease

  4. ABL → Tyrosine kinase → Targeted therapy

  5. APL (t15;17) → Think bleeding + ATRA


Practical example (mini-case)

Case: A 28-year-old woman presents with fatigue, bruising, and bleeding gums. Blood tests reveal pancytopenia. Bone marrow shows promyelocytes. Cytogenetics confirms t(15;17).

Question: What is the most appropriate initial treatment?

Answer: All-trans retinoic acid (ATRA)

Explanation: This is acute promyelocytic leukaemia. Early initiation of ATRA reduces mortality by correcting the differentiation block and lowering DIC risk—a classic MRCP Part 1 scenario.


Common pitfalls (exam traps)

  • Confusing t(8;14) (Burkitt) with t(14;18) (follicular lymphoma)

  • Forgetting that APL is a medical emergency

  • Assuming all AML translocations indicate poor prognosis (some are favourable)

  • Mixing up mantle cell lymphoma with follicular lymphoma

  • Over-revising molecular mechanisms instead of focusing on associations


How to revise efficiently (study checklist)

  • Memorise the core table (8–10 translocations)

  • Use flashcards for pattern recognition

  • Practise with timed questions via Start a mock test

  • Revise alongside haematology topics for context

  • Test recall daily—this is a memory-heavy topic

Medical student revising chromosomal translocations for MRCP Part 1 exam

FAQs

1. Which chromosomal translocation is most important for MRCP Part 1?

t(9;22) in CML is the most frequently tested, followed by t(15;17) in APL due to its treatment implications.

2. Why is t(15;17) considered an emergency?

It causes APL, which has a high risk of DIC. Prompt treatment with ATRA is life-saving.

3. Are chromosomal translocations only relevant in haematology?

Primarily yes for MRCP Part 1, as most exam questions focus on leukaemias and lymphomas.

4. How can I remember translocations easily?

Use grouped patterns (e.g., chromosome 14 = lymphoma) and practise repeated recall with question banks.

5. Do I need to know detailed molecular pathways?

No—focus on disease associations, prognosis, and treatment relevance.


Ready to start?

Chromosomal translocations are a high-yield, exam-friendly topic in MRCP Part 1. With a structured approach and repeated recall, this area can become a consistent scoring opportunity.

Continue your preparation with:

For deeper integration, pair this topic with haematology revision and clinical case practice.


Sources

 
 
 

Comments

bottom of page